<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5160CE88-742A-40D0-8C3B-711665EA2583"><gtr:id>5160CE88-742A-40D0-8C3B-711665EA2583</gtr:id><gtr:firstName>Ken</gtr:firstName><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9387F657-B9DB-4164-B995-7D2147B97EC5"><gtr:id>9387F657-B9DB-4164-B995-7D2147B97EC5</gtr:id><gtr:firstName>Sharon</gtr:firstName><gtr:surname>Peacock</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F40B6A38-1A7B-4153-A997-485BDCDF9E32"><gtr:id>F40B6A38-1A7B-4153-A997-485BDCDF9E32</gtr:id><gtr:firstName>Rodrigo</gtr:firstName><gtr:otherNames>Andres</gtr:otherNames><gtr:surname>Floto</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/877C0FAD-13BC-4F15-A199-F32B4E46D637"><gtr:id>877C0FAD-13BC-4F15-A199-F32B4E46D637</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Blundell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FN501864%2F1"><gtr:id>E53788F7-2E7A-4074-9332-D0C6B7805CF2</gtr:id><gtr:title>Cambridge-Chennai Centre Partnership on Antimicrobial Resistant Tuberculosis</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N501864/1</gtr:grantReference><gtr:abstractText>The need for a joint India-UK Centre Partnership focused on drug-resistant tuberculosis (TB) is founded on the scale of the problem both in India and globally, combined with the pressing need to develop new tools and therapeutics to combat it. There were 1,467,585 cases of TB notified in India during 2012 (the largest number of cases in any country worldwide), with a sharp rise in the number of people diagnosed with multidrug resistant (MDR) TB (from 308 to 16,588 laboratory confirmed cases between 2008 and 2012). Our partnership between the University of Cambridge and the National Institute for Research in Tuberculosis (NIRT) in Chennai, India, will bring together a multidisciplinary team to focus on novel diagnostics and therapeutics for TB. This includes the use of emerging sequence-based diagnostics to improve the accuracy of individual patient treatment for MDR and extensively drug resistant (XDR) TB; new drug targets for TB and prediction/investigation of the impact of resistance mutations based on modelling of bacterial genome data; the development of an in-depth understanding of the bacterial genes in diverse populations of Mycobacterium tuberculosis associated with so-called 'drug tolerance'; and novel approaches to treatment of TB based on immunomodulation (enhancement of autophagy and novel enhancers of T cell responsiveness). The Centre Partnership will generate a rich and lasting clinical and genomic dataset. Our objectives require detailed clinical and biological phenotyping and genotyping of patient cohorts, which can be mined to address future questions and will further enhance collaborative research to tackle the burden of drug-resistant TB. We will also innovate in training and knowledge transfer. Leveraging of novel technologies will increase relevant and collaborative research experience for UK and Indian investigators. Transfer of scientific training and technology to India enhances independent research capacity and fosters future international collaborative projects. This will be achieved through mobility and exchange of junior (training) and senior (discipline-hopping) researchers.</gtr:abstractText><gtr:technicalSummary>The need for a joint India-UK Centre Partnership focused on drug-resistant tuberculosis (TB) is founded on the scale of the problem both in India and globally, combined with the pressing need to develop new tools and therapeutics to combat it. There were 1,467,585 cases of TB notified in India during 2012 (the largest number of cases in any country worldwide), with a sharp rise in the number of people diagnosed with multidrug resistant (MDR) TB (from 308 to 16,588 laboratory confirmed cases between 2008 and 2012). Our partnership between the University of Cambridge and the National Institute for Research in Tuberculosis (NIRT) in Chennai, India, will bring together a multidisciplinary team to focus on novel diagnostics and therapeutics for TB. This includes the use of emerging sequence-based diagnostics to improve the accuracy of individual patient treatment for MDR and extensively drug resistant (XDR) TB; new drug targets for TB and prediction/investigation of the impact of resistance mutations based on modelling of bacterial genome data; the development of an in-depth understanding of the bacterial genes in diverse populations of Mycobacterium tuberculosis associated with so-called 'drug tolerance'; and novel approaches to treatment of TB based on immunomodulation (enhancement of autophagy and novel enhancers of T cell responsiveness). The Centre Partnership will generate a rich and lasting clinical and genomic dataset. Our objectives require detailed clinical and biological phenotyping and genotyping of patient cohorts, which can be mined to address future questions and will further enhance collaborative research to tackle the burden of drug-resistant TB. We will also innovate in training and knowledge transfer. Leveraging of novel technologies will increase relevant and collaborative research experience for UK and Indian investigators. Transfer of scientific training and technology to India enhances independent research capacity and fosters future international collaborative projects. This will be achieved through mobility and exchange of junior (training) and senior (discipline-hopping) researchers.</gtr:technicalSummary><gtr:fund><gtr:end>2019-04-10</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-04-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1149548</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:department><gtr:description>Shorten-TB</gtr:description><gtr:id>04169A3D-3FFE-4ABE-B0D0-C488667F6A68</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Drug screening and development</gtr:partnerContribution><gtr:piContribution>Analysis of structure, function and druggability of targets in tuberculosis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:department>Institute of Infectious Disease and Molecular Medicine (IIDMM)</gtr:department><gtr:description>Shorten-TB</gtr:description><gtr:id>F3F177BB-DBC2-417C-919B-F12B50844D9E</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Drug screening and development</gtr:partnerContribution><gtr:piContribution>Analysis of structure, function and druggability of targets in tuberculosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Tom Blundell appointed 8th Distinguished Technopreneur  2015, Singapore</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C63DAA7-99B5-4886-AA88-2CD293A6566A</gtr:id><gtr:impact>A discussion by Tom Blundell of research ecosystems, based on experience of forming companies in London and Cambridge, and looking at options for Singapore.

Discussions with Deputy Prime Minister of Singapore; visit of Head of Research to my company on the Science Park</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.science50.com.sg/dts.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Antimicrobial Resistance Workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>796C1E09-0980-4EFA-8BF5-73424B89C6D5</gtr:id><gtr:impact>Workshop discussing with policy makers, clinicians, scientists and research students in order to understand and cobalt impacts of antimicrobial resistance, mainly in tuberculosis</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint Workshop for PhD researchers</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8238BE3E-D298-4180-9DCC-6E3C1FE5EFA7</gtr:id><gtr:impact>Increased use of Genome3D databases and software

Questions from PhD about visiting lab</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wellcome Trust Sanger Institute Genomics for Clinicians course</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>38974206-C027-493B-A360-00F86BF36820</gtr:id><gtr:impact>A talk on pathogen genomics to clinical professionals attending a 1 week course to gain an understanding of the application of genomics to clinical practice</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Indian National Science Congress 2016, Mysore</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50BEF99A-B629-4EA4-AA58-CEB127E31C58</gtr:id><gtr:impact>General theme: Science &amp;amp; Technology for Indigenous Development in India. Tom Blundell Plenary Lecturer on Drug discovery for infectious disease in India where budgets have to be low. Open Source Drug Discovery, Biotech Spin-outs and Academia in Research Ecosystems</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.isc103.in</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Two lectures in University Pretoria, first to broad audience of students, policy makers, teachers; the second to students from the local Ndebele township</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2D327E6C-40DC-4BF6-9C76-ED2B9A643DE5</gtr:id><gtr:impact>Lectures leading to small discussions with groups of mainly Ndebele speaking undergraduate students; followed by visit to local township for discussions mediated by Dr Gugu Motshwene, and ex-tudent now lecturer in the University of Pretoria</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BIOINFORM?TICA ESTRUTURAL DE PROTE?NAS: MODELOS, ALGORITMOS E APLICA??ES BIOTECNOL?GICAS, Belo Horizonte, Brasil</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5438B71F-F86A-4960-BE8E-DB6031DF45AF</gtr:id><gtr:impact>A joint Brazil-UK workshop bringing together discussion human genetics and race in Brazil with our analyses of the effects of genome mutations on genetic disease, cancer and antimicrobial resistance</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>11999339</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR/BRC</gtr:department><gtr:description>UK Rapid Support Team</gtr:description><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>E6767313-5FFE-4C44-8FFC-1F52931EEEDC</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>6C7D7576-5A99-4684-8444-74F003A51C22</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>228F875C-A7E9-4B0C-B5DA-8A46F50E5FE9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1588479</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC antimicrobial resistance collaboration</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CA8AED22-452F-47F8-8C13-8E01A4525245</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Tom Blundell, Guest Lecturer International Chair of Therapeutic Innovation, an initiative of the Laboratory of Excellence in Research on Medication and Innovative Therapeutics: dissemination and training program.</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>0679E077-19A2-49D7-82F6-D5363D94255E</gtr:id><gtr:impact>Tom Blundell was Guest Lecturer and Discussant for three days in Paris as part of an initiative Medication and Innovative Therapeutics (LERMIT) as part of a dissemination and training program.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.labex-lermit.fr/en/formation/chaire-internationale-d-innovation-therapeutique</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chapter (on pathogen genomics) in Chief Medical Officer Volume II annual report on the tropic of genomics</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>62482351-5964-4786-A482-CD19EBF1AA78</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>President of UK Science Council (Tom Blundell)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>74705A7C-C5B0-4BFD-8E59-51AB15DEB3F6</gtr:id><gtr:impact>As President of Science Council I have overseen the introduction of professional accreditation, such as CSci, in across 40 professional societies. This is a major initiative to recognise the contributions of professional scientists in</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://sciencecouncil.org</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair, BBSRC (Tom Blundell)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8E1F52D7-18F3-4ACF-9687-682E996D6072</gtr:id><gtr:impact>The BBSRC has been a leading influence in basic and strategic research underpinning agriculture and food, biotechnology and animal and hum health (one Health)</gtr:impact><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://www.bbsrc.ac.uk</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A database of protein interactions, including protein-protein, protein ligand</gtr:description><gtr:id>92ECAA66-ECC3-4EB4-B504-57B42486FC75</gtr:id><gtr:impact>Used to understand drug interactions with protein targets</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Credo</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://marid.bioc.cam.ac.uk/credo</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Database of the structural proteome of Mycobacterium tuberculosis</gtr:description><gtr:id>412B7700-3FA1-45E4-AEBF-75628E5901E6</gtr:id><gtr:impact>Helpful in understanding the druggability of targets for antibacterials for tuberculosis</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Chopin</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://mordred.bioc.cam.ac.uk/chopin/about</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A machine learning approach to understanding the mechanisms by which mutations affect human genetic disease, drug resistance in cancer and antimicrobial resistance in human and infectious disease</gtr:description><gtr:id>47378E1E-C3AD-4B36-97DF-7A8F400D6EBB</gtr:id><gtr:impact>Demonstration that both genetic disease and drug resistance mechanisms include allosteric and protein interface affects, leading to suggestions about novel therapeutic mechanisms.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mCSM and mCSMlig</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:url>http://bleoberis.bioc.cam.ac.uk/mcsm/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>An updated webserver for the improved SDM, used for predicting the effects of mutations on protein stability. We have updated the environment-specific amino-acid substitution tables based on the current expanded PDB (a 5 fold increases in information), and introduced new residue conformations and interaction parameters, including packing density and residue depth.</gtr:description><gtr:id>AB83615F-5B0D-4504-A921-5722208E4186</gtr:id><gtr:impact>The updated server has been extensively tested using a wide benchmark containing 2690 point mutations from 132 different protein structures. Using an established benchmark, the revised method correlated well against the hypothetical reverse mutations, better than comparable methods built using machine-learning approaches, highlighting the strength of our knowledge-based approach for identifying stabilising mutations. Given a PDB file (a Protein Data Bank file format containing the three-dimensional coordinates of the protein atoms), and a point mutation, the server calculates the stability difference score between the wildtype and mutant protein.</gtr:impact><gtr:title>sdm</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:url>http://structure.bioc.cam.ac.uk/sdm2</gtr:url><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>Machine learning approach to predicting the impacts of mutations on protein stability and interactions with other proteins, nucleic acids, and small molecule ligands.</gtr:description><gtr:id>1B06A714-28C8-4E51-A72D-FAE1D46A5F28</gtr:id><gtr:impact>It has significant impact on understanding mutations in genetic disease and drug resistance</gtr:impact><gtr:title>mCSM</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:url>http://bleoberis.bioc.cam.ac.uk/mcsm/</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F0F7A05-D389-4DA1-8E4E-AC7825D553B0"><gtr:id>9F0F7A05-D389-4DA1-8E4E-AC7825D553B0</gtr:id><gtr:title>A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c7dd6175716e8411320509071577aa2"><gtr:id>1c7dd6175716e8411320509071577aa2</gtr:id><gtr:otherNames>Nikiforov PO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E4DEBDD-C801-42C2-BFA3-50A964524638"><gtr:id>0E4DEBDD-C801-42C2-BFA3-50A964524638</gtr:id><gtr:title>Enriching the annotation of Mycobacterium tuberculosis H37Rv proteome using remote homology detection approaches: insights into structure and function.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6331abdbfff41c52efe7118857c9d1d"><gtr:id>f6331abdbfff41c52efe7118857c9d1d</gtr:id><gtr:otherNames>Ramakrishnan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E632A707-2968-47C8-8223-EF1BB9392337"><gtr:id>E632A707-2968-47C8-8223-EF1BB9392337</gtr:id><gtr:title>The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.</gtr:title><gtr:parentPublicationTitle>ACS infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/00d7673f8c199287b692989e5f71228e"><gtr:id>00d7673f8c199287b692989e5f71228e</gtr:id><gtr:otherNames>Singh V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2373-8227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/97164B02-852D-4AFD-9234-A4BD0DFFECF4"><gtr:id>97164B02-852D-4AFD-9234-A4BD0DFFECF4</gtr:id><gtr:title>In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a71b52ab21ada6778475ab8ff066a341"><gtr:id>a71b52ab21ada6778475ab8ff066a341</gtr:id><gtr:otherNames>Pires DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/706AB579-DFAD-4FF8-91D3-03CC811945E4"><gtr:id>706AB579-DFAD-4FF8-91D3-03CC811945E4</gtr:id><gtr:title>Identifying Interactions that Determine Fragment Binding at Protein Hotspots.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c67d21e9dcc3c8006a4dd81be509c4f"><gtr:id>7c67d21e9dcc3c8006a4dd81be509c4f</gtr:id><gtr:otherNames>Radoux CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7904AAA9-7B3A-4760-BED4-2D4CD4C71E2A"><gtr:id>7904AAA9-7B3A-4760-BED4-2D4CD4C71E2A</gtr:id><gtr:title>Targeting tuberculosis using structure-guided fragment-based drug design.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c71d23a1158640e848407ba21616708"><gtr:id>6c71d23a1158640e848407ba21616708</gtr:id><gtr:otherNames>Mendes V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D568425B-498F-44F2-B6AC-135C1FFF072E"><gtr:id>D568425B-498F-44F2-B6AC-135C1FFF072E</gtr:id><gtr:title>mCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistance.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a71b52ab21ada6778475ab8ff066a341"><gtr:id>a71b52ab21ada6778475ab8ff066a341</gtr:id><gtr:otherNames>Pires DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7211A83A-6752-4C8B-9118-413B2EA0108D"><gtr:id>7211A83A-6752-4C8B-9118-413B2EA0108D</gtr:id><gtr:title>Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5bd2c9145210fbc1d7f0d944fc061a72"><gtr:id>5bd2c9145210fbc1d7f0d944fc061a72</gtr:id><gtr:otherNames>Luciani R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7144C257-5CEA-426C-A436-1026187B4707"><gtr:id>7144C257-5CEA-426C-A436-1026187B4707</gtr:id><gtr:title>Structure-guided, target-based drug discovery - exploiting genome information from HIV to mycobacterial infections.</gtr:title><gtr:parentPublicationTitle>Postepy biochemii</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6dbdbde4ac8e3cf1a59a1e55e70fb328"><gtr:id>6dbdbde4ac8e3cf1a59a1e55e70fb328</gtr:id><gtr:otherNames>Malhotra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0032-5422</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N501864/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>C11BDEA9-7D9D-4728-B6A9-31032921B328</gtr:id><gtr:text>Newton</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>